IDEXX Laboratories Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über IDEXX Laboratories Inc Unternehmen

IDEXX Laboratories, Inc. develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, dairy and water testing industries. The Company also provides human medical point-of-care and laboratory diagnostics. Its segments include Companion Animal Group (CAG), Water quality products (Water), and Livestock, Poultry and Dairy (LPD). The CAG segment offers diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment provides testing solutions for accurate detection and quantification of various microbiological parameters in water. The LPD segment provides diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, and to improve the quality and safety of milk.

Unternehmensinformationen

BörsenkürzelIDXX

Name des UnternehmensIDEXX Laboratories Inc

IPO-datumJun 21, 1991

Gegründet am1983

CEOMr. Andrew Emerson

Anzahl der mitarbeiter11000

WertpapierartOrdinary Share

GeschäftsjahresendeJun 21

AddresseOne Idexx Drive

StadtWESTBROOK

BörseNASDAQ Global Select Consolidated

LandUnited States of America

Postleitzahl04092-2041

Telefon12075560300

Websitehttps://www.idexx.com/

BörsenkürzelIDXX

IPO-datumJun 21, 1991

Gegründet am1983

Führungskräfte

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Michael Erickson, Ph.D.

Executive Vice President and General Manager, Point of Care Diagnostics and Telemedicine

12.58K

+18.05%

Dr. Sophie V. Vandebroek, Ph.D.

Independent Director

8.69K

+3.11%

Mr. Lawrence D. (Larry) Kingsley

Independent Chairman of the Board

8.23K

+4.39%

Mr. Michael J. Lane

Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology

7.70K

+0.61%

Ms. Sharon E. Underberg

Executive Vice President, General Counsel, Corporate Secretary

5.93K

+8.90%

Mr. Daniel M. (Dan) Junius

Independent Director

3.00K

+9.56%

Mr. Andrew Emerson

Executive Vice President, Chief Executive Officer, Treasurer

2.40K

--

Mr. Michael Schreck

Executive Vice President and General Manager, Veterinary Software and Services, Corporate Accounts and Customer Experience

1.92K

+112.86%

Mr. Bruce L. Claflin

Independent Director

1.72K

--

Dr. Stuart M. Essig, Ph.D.

Independent Director

1.09K

+31.76%

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Michael Erickson, Ph.D.

Executive Vice President and General Manager, Point of Care Diagnostics and Telemedicine

12.58K

+18.05%

Dr. Sophie V. Vandebroek, Ph.D.

Independent Director

8.69K

+3.11%

Mr. Lawrence D. (Larry) Kingsley

Independent Chairman of the Board

8.23K

+4.39%

Mr. Michael J. Lane

Executive Vice President and General Manager, Global Reference Laboratories, Diagnostic Solutions and Information Technology

7.70K

+0.61%

Ms. Sharon E. Underberg

Executive Vice President, General Counsel, Corporate Secretary

5.93K

+8.90%

Mr. Daniel M. (Dan) Junius

Independent Director

3.00K

+9.56%

Umsatzaufteilung

Währung: USDAktualisiert: Sun, Apr 6

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

CAG Diagnostics recurring revenue

3.13B

80.29%

Reference laboratory diagnostic and consulting services

1.34B

34.28%

IDEXX VetLab consumables

1.30B

33.44%

Rapid assay products

359.75M

9.23%

CAG Diagnostics capital - instruments

312.62M

8.02%

Other

-2.54B

-65.27%

Nach RegionUSD

Name

Umsatz

Anteil

United States

2.53B

64.99%

Other Euorpe

196.31M

5.04%

Germany

173.68M

4.46%

Canada

152.88M

3.92%

United Kingdom

134.63M

3.45%

Other

706.82M

18.14%

Nach Geschäftsbereich

Nach Region

Nach GeschäftsbereichUSD

Name

Umsatz

Anteil

CAG Diagnostics recurring revenue

3.13B

80.29%

Reference laboratory diagnostic and consulting services

1.34B

34.28%

IDEXX VetLab consumables

1.30B

33.44%

Rapid assay products

359.75M

9.23%

CAG Diagnostics capital - instruments

312.62M

8.02%

Other

-2.54B

-65.27%

Aktionärsstatistik

Aktualisiert: Sat, May 17

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

12.21%

BlackRock Institutional Trust Company, N.A.

6.76%

State Street Global Advisors (US)

4.54%

Fundsmith LLP

3.29%

Geode Capital Management, L.L.C.

3.00%

Other

70.20%

Aktionäre

Anteil

The Vanguard Group, Inc.

12.21%

BlackRock Institutional Trust Company, N.A.

6.76%

State Street Global Advisors (US)

4.54%

Fundsmith LLP

3.29%

Geode Capital Management, L.L.C.

3.00%

Other

70.20%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

44.48%

Investment Advisor/Hedge Fund

41.16%

Research Firm

4.01%

Pension Fund

2.24%

Bank and Trust

2.04%

Hedge Fund

1.86%

Sovereign Wealth Fund

1.35%

Individual Investor

0.68%

Family Office

0.48%

Other

1.71%

Institutionelle Beteiligung

Aktualisiert: Sun, Jan 19

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q1

2230

77.53M

95.67%

-2.91M

2024Q4

2242

76.14M

93.59%

-5.30M

2024Q3

2152

77.90M

94.66%

-4.67M

2024Q2

2140

80.09M

96.98%

-924.14K

2024Q1

2154

77.56M

93.40%

-2.57M

2023Q4

2187

77.94M

93.84%

-2.83M

2023Q3

2153

79.23M

95.34%

-677.16K

2023Q2

2157

77.53M

93.40%

-1.56M

2023Q1

2158

77.14M

92.96%

-2.07M

2022Q4

2124

77.44M

93.49%

-2.66M

Aktionärsaktivitäten

Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

9.67M

11.94%

-29.32K

-0.30%

Dec 31, 2024

BlackRock Institutional Trust Company, N.A.

5.32M

6.57%

-239.97K

-4.31%

Dec 31, 2024

State Street Global Advisors (US)

3.64M

4.49%

+24.20K

+0.67%

Dec 31, 2024

Fundsmith LLP

2.66M

3.29%

-1.31K

-0.05%

Dec 31, 2024

Geode Capital Management, L.L.C.

2.30M

2.83%

+37.73K

+1.67%

Dec 31, 2024

Baron Capital Management, Inc.

2.01M

2.47%

+82.26K

+4.28%

Dec 31, 2024

T. Rowe Price Associates, Inc.

1.05M

1.29%

-375.34K

-26.42%

Dec 31, 2024

Invesco Capital Management (QQQ Trust)

1.69M

2.09%

+22.74K

+1.36%

Feb 28, 2025

BlackRock Asset Management Ireland Limited

1.13M

1.39%

+36.40K

+3.33%

Dec 31, 2024

Principal Global Investors (Equity)

711.20K

0.88%

-19.27K

-2.64%

Dec 31, 2024

Verbundene ETFs

Aktualisiert: Fri, Jun 6

Name

Anteil

ProShares Pet Care ETF

11.01%

iShares U.S. Medical Devices ETF

5.07%

First Trust Water ETF

4.92%

First Trust NASDAQ-100 Ex-Technology Sector Index Fund

2.24%

SPDR S&P Health Care Equipment ETF

2.22%

Putnam Sustainable Future ETF

2.11%

Invesco S&P 500 Equal Weight Health Care ETF

2.1%

First Trust S&P 500 Economic Moat Index ETF

2.04%

American Century Mid Cap Growth Impact ETF

1.93%

Adaptive Core ETF

1.84%

ProShares Pet Care ETF

Anteil11.01%

iShares U.S. Medical Devices ETF

Anteil5.07%

First Trust Water ETF

Anteil4.92%

First Trust NASDAQ-100 Ex-Technology Sector Index Fund

Anteil2.24%

SPDR S&P Health Care Equipment ETF

Anteil2.22%

Putnam Sustainable Future ETF

Anteil2.11%

Invesco S&P 500 Equal Weight Health Care ETF

Anteil2.1%

First Trust S&P 500 Economic Moat Index ETF

Anteil2.04%

American Century Mid Cap Growth Impact ETF

Anteil1.93%

Adaptive Core ETF

Anteil1.84%

Dividende

In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split

Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten

IDEXX Laboratories Inc

527.924USD

IDEXX Laboratories Inc

527.924

Übersicht

Unternehmen